Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal

References

• Bruggmann P, Berg T, Øvrehus ALH, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014;21 Suppl 1:5–33.
   PubMed Web of Science ®Google Scholar
• Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–176.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Hepatitis C 2021. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (Cited 2022 Apr 7).
   Google Scholar
• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1):S45–57.
   PubMedGoogle Scholar
• Albillos Martínez A, Cañada Merino JL, Molero García JM, et al. Consenso de recomendaciones para el diagnóstico precoz, la prevención y la atención clínica de la hepatitis C en Atención Primaria 2017. https://www.semfyc.es/wp-content/uploads/2017/02/CRIPRE_DOCUMENTO-CONSENSO-CRIPRE_AEEH_SEMG_SMERGEN_semFYC-VERSION-FINAL-2017.pdf.
   Google Scholar
• Burgui C, Martín C, Aguinaga A, et al. Prevalence and detection of undiagnosed active hepatitis C virus infections in Navarre, Spain, 2017-2019. Rev Esp Enferm Dig. 2021;113(1):28–34.
   PubMed Web of Science ®Google Scholar
• Allison RD, Tong X, Moorman AC, et al. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010. J Hepatol. 2015;63(4):822–828.
   PubMed Web of Science ®Google Scholar
• Mazzaro C, Quartuccio L, Adinolfi LE, et al. A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy. Viruses. 2021;13(11):2249.
   PubMed Web of Science ®Google Scholar
• Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562–569.
   PubMed Web of Science ®Google Scholar
• Juanbeltz R, Pérez-García A, Aguinaga A, et al. Progress in the elimination of hepatitis C virus infection: a population-based cohort study in Spain. PLoS One. 2018;13(12):e0208554.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016–2021 2016. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1&isAllowed=y.
   Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–982.
   PubMed Web of Science ®Google Scholar
• Hézode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147. DOI:10.1053/J.GASTRO.2014.03.051.
   Google Scholar
• Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64(2):370–380.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology. 2016;64(2):360–369.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–1603.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373(27):2599–2607.
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 Infection. N Engl J Med. 2015;373(27):2608–2617.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–1493.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Foster GR, Wang S, et al. Glecaprevir–Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–369.
   PubMed Web of Science ®Google Scholar
• Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol. 2017;66(1):39–47.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Craxí A, Zuckerman E, et al. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: a meta-analysis. J Viral Hepat. 2017;24(11):936–943.
   PubMed Web of Science ®Google Scholar
• Degasperi E, Spinetti A, Lombardi A, et al. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol. 2019;71(6):1106–1115.
   PubMed Web of Science ®Google Scholar
• Ministry of Health SS and E. Strategic plan for tackling hepatitis C in the Spanish national health system 2015:1–94. https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/PEAHC_eng.pdf.
   Google Scholar
• Ministry of Health SS and E. Informe de situación del Plan Estratégico para el Abordaje de la Hepatitis C Cónica presentado al Congreso Interterritorial del SNS. 2017. https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/informeSituacionPEAHCPresentadoCISNS_Jun2017.pdf.
   Google Scholar
• Ministry of Health SS and E. Guía de cribado de la infección por el VHC. 2020. https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/GUIA_DE_CRIBADO_DE_LA_INFECCION_POR_EL_VHC_2020.pdf.
   Google Scholar
• Juanbeltz R, Martínez-Baz I, San Miguel R, et al. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS One. 2018;13. DOI:10.1371/JOURNAL.PONE.0205277.
   Google Scholar
• Gamkrelidze I, Pawlotsky JM, Lazarus JV, et al. Progress towards hepatitis C virus elimination in high-income countries: an updated analysis. Liver Int. 2021;41(3):456–463.
   PubMed Web of Science ®Google Scholar
• Flisiak R, Zarębska-Michaluk D, Frankova S, et al. Is elimination of HCV in 2030 realistic in Central Europe. Liver Int. 2021;41(S1):56–60.
   PubMedGoogle Scholar
• Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology. 1996;24(2):289–293.
   PubMed Web of Science ®Google Scholar
• Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.
   PubMedGoogle Scholar
• Burgui C, Martín C, Juanbeltz R, et al. Recapture of patients with an incomplete diagnosis of hepatitis C virus infection. Rev Esp Enferm Dig. 2020;112:525–531.
   PubMed Web of Science ®Google Scholar
• Amele S, Sandri AK, Rodger A, et al. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. HIV Med. 2022;23(6):684–692.
   PubMed Web of Science ®Google Scholar
• Ingiliz P, Martin TC, Rodger A, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol. 2017;66(2):282–287.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Developing a national strategy for the prevention and control of sexually transmitted infections 2019. https://www.ecdc.europa.eu/sites/default/files/documents/strategies-to-control-STIs.pdf.
   Google Scholar
• Juanbeltz Zurbano R, Zozaya JM, Repáraz J, et al. Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C. An Sist Sanit Navar. 2017;40:57–66.
   PubMed Web of Science ®Google Scholar
• Mar J, Ibarrondo O, Martínez-Baz I, et al. Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals. Rev Esp Enferm Dig. 2018;110:621–628.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: final update of the series☆. J Hepatol. 2020;73:1170–1218.
   PubMed Web of Science ®Google Scholar
• Observatory HCV Collaborators P. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022. 10.1016/S2468-1253(21)00472-6
   Web of Science ®Google Scholar
• Buti M, Domínguez-Hernández R, Casado MA. Impact of the COVID-19 pandemic on HCV elimination in Spain. J Hepatol. 2021;74(5):1246–1248.
   PubMed Web of Science ®Google Scholar
• Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74(1):31–36.
   PubMed Web of Science ®Google Scholar
• Domínguez-Domínguez L, Lagarde M, Bisbal O, et al. Sustained virological response at week 12 after interferon-free therapy as criterion for HCV cure definition: validation in a real-life cohort of HIV-coinfected patients. Enferm Infecc Microbiol Clin (Engl Ed). 2020;38(6):275–278.
   PubMedGoogle Scholar
• Ridruejo E, Pereson MJ, Flichman DM, et al. Hepatitis C virus treatment failure: clinical utility for testing resistance-associated substitutions. World J Hepatol. 2021;13(9):1069–1078.
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Safreed-Harmon K, Thursz MR, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018;38(3):181–192.
   PubMed Web of Science ®Google Scholar
• V LJ, Picchio CA, Byrne C, et al. A global systematic review of hepatitis C elimination efforts through micro-elimination. Semin Liver Dis. 2022;42(2):159–172.
   PubMedGoogle Scholar
• Schwarz T, Horváth I, Fenz L, et al. Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: a systematic review and practical considerations from an expert panel consultation. Int J Drug Policy. 2022;102:103588.
   PubMed Web of Science ®Google Scholar
• Künzler-Heule P, Fierz K, Schmidt AJ, et al. Response to a sexual risk reduction intervention provided in combination with hepatitis C treatment by HIV/HCV co-infected men who have sex with men: a reflexive thematic analysis. BMC Infect Dis. 2021;21(1):319.
   PubMed Web of Science ®Google Scholar
• Braun DL, Hampel B, Ledergerber B, et al. A treatment-as-prevention trial to eliminate hepatitis C among men who have sex with men living with human immunodeficiency virus (HIV) in the Swiss HIV cohort study. Clin Infect Dis. 2021;73(7):e2194–202.
   PubMed Web of Science ®Google Scholar
• Cabezas J, Llerena S, Mateo M, et al. Hepatitis C micro-elimination beyond prison walls: navigator-assisted test-and-treat strategy for subjects serving non-custodial sentences. Diagnostics (Basel). 2021;11(5):877. DOI:10.3390/diagnostics11050877.
   PubMedGoogle Scholar
• Sonneveld MJ, Veldhuijzen IK, van de Laar TJW, et al. Decrease in viral hepatitis diagnoses during the COVID-19 pandemic in the Netherlands. J Hepatol. 2022;77(3):896–897.
   PubMedGoogle Scholar
• Mangia A, Cotugno R, Cocomazzi G, et al. Hepatitis C virus micro-elimination: where do we stand? World J Gastroenterol. 2021;27(16):1728–1737.
   PubMed Web of Science ®Google Scholar
• Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021 45;45(3):101596.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Boesecke C, Golsabahi-Broclawski S, et al. Hepatitis C virus: current steps toward elimination in Germany and barriers to reaching the 2030 goal. Heal Sci Reports. 2021; 4: e290.
   PubMedGoogle Scholar
• Capraru C, Feld JJ. Remaining challenges in HCV elimination. J Hepatol. 2021;74(4):964–965.
   PubMed Web of Science ®Google Scholar
• Laury J, Hiebert L, Ward JW. Impact of COVID-19 response on hepatitis prevention care and treatment: results from global survey of providers and program managers. Clin Liver Dis. 2021;17(1):41–46.
   Google Scholar